New studies in type 2 diabetes mellitus (T2DM) suggest sodium-glucose cotransporter 2 (SGLT-2) inhibitors reduce all-cuase mortality vs other newer classes of diabetes drugs; support efficacy of a telehealth program for the treatment of T2DM; and assess current USPSTF screening recommendations for detecting diabetes.Â 

New diabetes studies find SGLT2i may reduce all-cause mortality; that telemedicine can improve T2DM care; and that broader screening criteria are better.